# Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

> **NCT00335179** · PHASE2 · COMPLETED · sponsor: **Graceway Pharmaceuticals, LLC** · enrollment: 17 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Aldara (imiquimod 5% cream)
- **DRUG:** Vehicle cream

## Key facts

- **NCT ID:** NCT00335179
- **Lead sponsor:** Graceway Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-07
- **Final completion:** 2003-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2010-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335179, "Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00335179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*